Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Royalty Pharma Plc Cl A (NQ: RPRX )

28.19 +0.46 (+1.66%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,846,655
Open 27.82
Bid (Size) 28.10 (2)
Ask (Size) 29.00 (1)
Prev. Close 27.73
Today's Range 27.82 - 28.41
52wk Range 25.20 - 31.66
Shares Outstanding 388,132,400
Dividend Yield 2.84%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
Jim Cramer discusses Snowflake, Royalty Pharma, Core Scientific and Ally Financial on "Mad Money Lightning Round." 
Via Benzinga
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q2 2024
RPRX stock results show that Royalty Pharma missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace

Performance

YTD
-0.28%
-0.28%
1 Month
-1.67%
-1.67%
3 Month
+5.90%
+5.90%
6 Month
-9.15%
-9.15%
1 Year
-4.63%
-4.63%

More News

Read More
Royalty Pharma Reports Second Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Appoints Molly Sawaya as Executive Vice President, Head of Human Capital
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Announce Second Quarter 2024 Financial Results on August 8, 2024
From Royalty Pharma plc
Via GlobeNewswire
NASDAQ:RPRX: good value for what you're paying.
Via Chartmill
Royalty Pharma Declares Third Quarter 2024 Dividend
From Royalty Pharma plc
Via GlobeNewswire
Cytokinetics' Wild Ride: Can Investors Forgive The Royalty Pharma Deal?
Via Investor's Business Daily
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024
Via InvestorPlace
7 Biotech Stocks to Buy on the Dip: June 2024
Via InvestorPlace
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
June’s Biotech Boom: 3 Stocks to Buy for a Summertime Surge
Via InvestorPlace
Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes
From Royalty Pharma plc
Via GlobeNewswire
Why Is Agios Pharmaceuticals Stock Trading Higher On Tuesday?
Via Benzinga
Exposures Product Safety
Agios Pharmaceuticals Inks $905 Million Deal For Cancer Drug; Shares Poised To Break Out
Via Investor's Business Daily
Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million
From Royalty Pharma plc
Via GlobeNewswire
Heart Disease-Focused Cytokinetics Operations Are On Track Despite Acquisition Uncertainty, Analysts Observe
Via Benzinga
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
From Royalty Pharma plc; Cytokinetics
Via GlobeNewswire
7 Dividend Stocks to Buy at a 52-Week Low
Via InvestorPlace
Royalty Pharma to Present at Upcoming Investor Conferences
From Royalty Pharma plc
Via GlobeNewswire
RPRX Stock Earnings: Royalty Pharma Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Royalty Pharma Reports First Quarter 2024 Results
From Royalty Pharma plc
Via GlobeNewswire
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
From Royalty Pharma plc
Via GlobeNewswire
Amgen Reports Better-Than-Expected Q1 Results, $50M Milestone Payment
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.